News Actinium radioligand aces AML trial as filings beckon Survival doubled when Iomab-B was used as a conditioning regimen before a stem cell transplant.
News Actinium eyes filing as conditioning drug for AML aces trial Actinium Pharma is on course to submit its targeted radiotherapy for acute myeloid leukaemia (AML) patients needing a bone mar
News Iambic prices its IPO, seeking to raise up to $160m AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
